Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon 中 contact icon menu icon
Medicilon Logo
|
search icon close search icon 中 contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 20 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research
Biology Research
Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients
Pharmaceutical preparation
Analytical Method Development and Quality Control
CMC Filings
Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics
Drug Safety Evaluation
DMPK
Bioanalysis
IND Filings
01 One-stop Integrated Services
Liposome Drug Development
Drug Discovery
Pharmaceutical Research
Preclinical Research
Botanical Drug Preclinical R&D
02 Innovative Drug Services
ADC
PROTAC
mRNA Vaccine
Cellular Immunotherapies
Nucleic Acid Drug
Peptide Drug Conjugate (PDC)
Antibody
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection
Metabolite Identification (MetID)
Drug Forming Research
Flow Cytometry Technology
SEND Format Conversion
Flow Sorting
NanoString nCounter Detection
Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model
Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease
05 Advanced Preparation R&D
Inhalation drug
Ophthalmic drug
Skin Topical Preparation
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
CAREERS
Talent Development
Campus Recruitment
Recruitment
Campus Recruitment
Campus Recruitment
Recruitment
Recruitment
News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2024-07-22Medicilon Events
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
Learn more
2024-07-22Medicilon Events
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Dec 28,2022
Medicilon participated in the annual meeting of the American Chinese Biomedical Technology Association on Christmas Eve
The 27th Annual Chinese Biopharmaceutical Association (CBA) Meeting will be held on December 17, 2022, at the Marriott Washingtonian Center in Maryland!
More
Medicilon participated in the annual meeting of the American Chinese Biomedical Technology Association on Christmas Eve
Dec 28,2022
Listed for 3 consecutive years! Medicilon won the "Top 20 Chinese R&D CRO Enterprises in 2022"
Shanghai Medicilon Inc. (Medicilon), as a one-stop pharmaceutical preclinical R&D service platform in China, was once again selected as one of the "Top 20 Chinese R&D CRO Enterprises in 2022" by virtue of its solid R&D strength. This is the 3rd consecutive year that Medicilon has won this honorary title!
More
Listed for 3 consecutive years! Medicilon won the "Top 20 Chinese R&D CRO Enterprises in 2022"
Dec 28,2022
Translational Medicine - Accelerate the R&D process of innovative drugs and precision medicine
The Medicilon translational medicine platform has an experienced professional technical team, starting from the mechanism of action of drug targets and the clinical application of biomarkers, based on the discovery and validation of biomarkers, combining a variety of different technology platforms and state-of-art instruments, and creating multiple bioanalytical methods, to reduce the cost and time of drug R&D, and provide diverse and efficient services for different types of drugs, different kinds of pharmaceutical companies and projects at different R&D stages.
More
Translational Medicine - Accelerate the R&D process of innovative drugs and precision medicine
Dec 22,2022
Medicilon wish you a merry christmas
Christmas is coming up! Wishing you all the Hope, Wonder, and Joy! Have a delicious time!
More
Medicilon wish you a merry christmas
Dec 09,2022
Holiday Promotion: Medicilon Antibody Development Technology Service with Discount Price
Medicilon Antibody Development Technical Service is here to help you develop new drugs with high cost performance, high efficiency and high quality.
More
Holiday Promotion: Medicilon Antibody Development Technology Service with Discount Price
Dec 09,2022
Congratulation to the Expansion of Medicilon Drug Research and Development Laboratory
On December 4th, with the completion of the last concrete pouring, the expansion project of the drug research and development laboratory of Shanghai Medicilon Inc has been completed. This marks the further strengthening of Medicilon's one-stop biopharmacetical preclinical R&D service platform capabilities.
More
Congratulation to the Expansion of Medicilon Drug Research and Development Laboratory
Nov 22,2022
Medicilon and Infinite Intelligence Pharma Reached a Strategic Collaboration
​Recently, Shanghai Medicilon Inc. (Medicilon) signed a strategic collaboration agreement with Infinite Intelligence Pharma (IIP).
More
Medicilon and Infinite Intelligence Pharma Reached a Strategic Collaboration
Nov 22,2022
Medicilon was Elected as the Director Unit of The Listed Companies Association of Shanghai
On November 10, 2022, the Listed Companies Association of Shanghai held the 4th member meeting of the association and the 1st meeting of council of the association through the online platform of East Money information. The meeting was presided over by Yuan Yi, Secretary of the Association, and supervised by the Shanghai Oriental Notary Public Office.
More
Medicilon was Elected as the Director Unit of The Listed Companies Association of Shanghai
Nov 18,2022
Medicilon FTE services & FFS services - flexible and efficient cooperation model
Medicilon offer a full range of chemistry Research services covering all phases of your project requirements, and clients can work with us under either the FFS (project-based payment) or FTE (full-time equivalent service) models.
More
Medicilon FTE services & FFS services - flexible and efficient cooperation model
Nov 08,2022
Medicilon assists Beijing Peptide's clinical application of semaglutide injection of semaglutide was accepted by CDE; ZT002 was promoted in China, US and Australia Filing
On August 29, 2022, Beijing Peptide Biomedical Technology Co., Ltd. (Bejing Peptide) ZT002 injection was approved by the Australian Human Research Ethics Committee for Phase I clinical trials.
More
Medicilon assists Beijing Peptide's clinical application of semaglutide injection of semaglutide was accepted by CDE; ZT002 was promoted in China, US and Australia Filing
Nov 08,2022
Medicilon Appoints Dr. Renzong Xie DABT as Vice President of Toxicology Research
Recently, Shanghai Medicilon Inc. (Medicilon) appointed Dr. Renzong Xie as the Vice President of Toxicology Research Department.
More
Medicilon Appoints Dr. Renzong Xie DABT as Vice President of Toxicology Research
Oct 28,2022
Assisting the development of the Chinese new anti-influenza drug ADC189 preparation, Medicilon and AnDiCon Bio reached a collaboration
On October 19, AnDiCon Bio (AnDiCon) officially launched the phase II/III clinical study of ADC189 tablets, a new class 1 anti-influenza drug. The drug is expected to become the first class 1 innovative anti-influenza drug independently developed and approved for marketing in China.
More
Assisting the development of the Chinese new anti-influenza drug ADC189 preparation, Medicilon and AnDiCon Bio reached a collaboration
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->